Symbols / ONCY $1.15 +2.68% Oncolytics Biotech Inc.

Healthcare • Biotechnology • Canada • NCM
ONCY Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Fundamentals
Scroll to Statements
Market Cap 133.55M Enterprise Value 128.91M Income -28.76M Sales — Book/sh 0.00 Cash/sh 0.04
Dividend Yield — Payout 0.00% Employees 29 IPO — P/E — Forward P/E -4.27
PEG — P/S — P/B 1601.89 P/C — EV/EBITDA -4.50 EV/Sales —
Quick Ratio 0.95 Current Ratio 1.12 Debt/Eq — LT Debt/Eq — EPS (ttm) -0.30 EPS next Y -0.27
EPS Growth — Revenue Growth — Earnings 2026-05-14 ROA -170.96% ROE — ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 116.13M Shs Float 113.67M Short Float 5.44%
Short Ratio 8.08 Short Interest — 52W High 1.51 52W Low 0.33 Beta 0.99 Avg Volume 1.28M
Volume 732.39K Target Price $5.15 Recom Buy Prev Close $1.12 Price $1.15 Change 2.68%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.15
Mean price target
2. Current target
$1.15
Latest analyst target
3. DCF / Fair value
$-1.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.15
Low
$2.96
High
$10.11
Mean
$5.15

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-17 main HC Wainwright & Co. Buy → Buy $10
2025-08-13 init Lake Street — → Buy $7
2025-05-21 reit HC Wainwright & Co. Buy → Buy $5
2025-05-16 down Jones Trading Buy → Hold —
2025-03-10 main Maxim Group Buy → Buy $3
2025-03-10 reit HC Wainwright & Co. Buy → Buy $5
2025-03-10 main RBC Capital Outperform → Outperform $5
2025-02-03 reit HC Wainwright & Co. Buy → Buy $5
2024-11-14 reit HC Wainwright & Co. Buy → Buy $5
2024-09-19 reit HC Wainwright & Co. Buy → Buy $5
2024-08-21 reit HC Wainwright & Co. Buy → Buy $5
2024-05-14 reit HC Wainwright & Co. Buy → Buy $5
2024-04-04 init Raymond James — → Outperform $3
2024-03-08 main HC Wainwright & Co. Buy → Buy $5
2024-02-14 reit HC Wainwright & Co. Buy → Buy $5
2024-01-19 reit HC Wainwright & Co. Buy → Buy $5
2024-01-04 reit HC Wainwright & Co. Buy → Buy $5
2023-11-13 main HC Wainwright & Co. Buy → Buy $5
2023-08-16 reit HC Wainwright & Co. Buy → Buy $15
2023-06-29 reit HC Wainwright & Co. Buy → Buy $15
News
RSS: Latest ONCY news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-12 Andrews (Patricia S.) Director of Issuer — 35,400 $0.86 $30,302
2026-02-12 Brown (Deborah Margaret) Director of Issuer — 25,000 $0.85 $21,250
2026-02-12 Hagerman (Allison) Senior Officer of Issuer — 10,000 $0.83 $8,300
2026-02-12 Heineman (Thomas Ph.D.) Senior Officer of Issuer — 12,132 $0.83 $10,033
2026-02-12 Kelly (Jared Ryan) Senior Officer of Issuer — 29,500 $0.84 $24,839
2026-02-12 Look (Kirk) Senior Officer of Issuer — 12,000 $0.84 $10,104
2026-02-12 Pisano (Wayne) Director of Issuer — 30,000 $0.84 $25,350
2026-02-12 Seizinger (Bernd R.) Director of Issuer — 40,000 $0.85 $33,880
2026-02-11 Aromando (Andrew P) Senior Officer of Issuer — 29,600 $0.86 $25,426
2026-02-11 Kelly (Jared Ryan) Senior Officer of Issuer — 5,600 $0.84 $4,681
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
28.73
+12.46%
25.54
+0.28%
25.47
+28.40%
19.84
Research And Development
13.31
-13.79%
15.44
+15.69%
13.35
+17.40%
11.37
Selling General And Administration
15.41
+52.60%
10.10
-14.55%
11.82
+44.51%
8.18
General And Administrative Expense
15.41
+52.60%
10.10
-14.55%
11.82
+44.51%
8.18
Salaries And Wages
3.86
+13.33%
3.41
+14.60%
2.97
+4.07%
2.86
Other Gand A
11.55
+72.59%
6.69
-24.35%
8.85
+66.21%
5.32
Other Operating Expenses
—
—
—
—
Total Expenses
28.73
+12.46%
25.54
+0.28%
25.47
+28.40%
19.84
Operating Income
-28.73
-12.46%
-25.54
-0.28%
-25.47
-28.40%
-19.84
Total Operating Income As Reported
-28.73
-12.46%
-25.54
—
—
EBITDA
-28.66
-12.57%
-25.45
-1.14%
-25.17
-28.74%
-19.55
Normalized EBITDA
-28.70
-5.05%
-27.32
+5.11%
-28.79
-38.69%
-20.76
Reconciled Depreciation
0.07
-19.54%
0.09
-71.36%
0.30
+5.18%
0.29
EBIT
-28.73
-12.46%
-25.54
-0.28%
-25.47
-28.40%
-19.84
Total Unusual Items
0.05
-97.48%
1.87
-48.48%
3.63
+199.15%
1.21
Total Unusual Items Excluding Goodwill
0.05
-97.48%
1.87
-48.48%
3.63
+199.15%
1.21
Net Income
-28.76
-26.17%
-22.79
-8.96%
-20.92
-14.32%
-18.30
Pretax Income
-28.68
-26.35%
-22.70
-8.89%
-20.85
-14.31%
-18.24
Net Non Operating Interest Income Expense
0.39
-60.41%
0.97
-2.46%
1.00
+156.93%
0.39
Net Interest Income
0.39
-60.41%
0.97
-2.46%
1.00
+156.93%
0.39
Interest Income Non Operating
0.39
-60.41%
0.97
-2.46%
1.00
+156.93%
0.39
Interest Income
0.39
-60.41%
0.97
-2.46%
1.00
+156.93%
0.39
Other Income Expense
-0.34
-118.25%
1.87
-48.48%
3.63
+199.15%
1.21
Other Non Operating Income Expenses
-0.39
—
—
—
Gain On Sale Of Security
0.05
-97.48%
1.87
-48.48%
3.63
+199.15%
1.21
Tax Provision
0.08
-16.84%
0.10
+29.92%
0.07
+18.14%
0.06
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.01
-97.48%
0.39
-48.48%
0.76
+199.15%
0.25
Net Income Including Noncontrolling Interests
-28.76
-26.17%
-22.79
-8.96%
-20.92
-14.32%
-18.30
Net Income From Continuing Operation Net Minority Interest
-28.76
-26.17%
-22.79
-8.96%
-20.92
-14.32%
-18.30
Net Income From Continuing And Discontinued Operation
-28.76
-26.17%
-22.79
-8.96%
-20.92
-14.32%
-18.30
Net Income Continuous Operations
-28.76
-26.17%
-22.79
-8.96%
-20.92
-14.32%
-18.30
Normalized Income
-28.80
-18.65%
-24.27
-2.04%
-23.78
-23.51%
-19.26
Net Income Common Stockholders
-28.76
-26.17%
-22.79
-8.96%
-20.92
-14.32%
-18.30
Diluted EPS
—
-0.29
+7.57%
-0.31
+2.45%
-0.32
Basic EPS
—
-0.29
+7.57%
-0.31
+2.45%
-0.32
Basic Average Shares
—
76.48
+13.10%
67.62
+16.53%
58.03
Diluted Average Shares
—
76.48
+13.10%
67.62
+16.53%
58.03
Diluted NI Availto Com Stockholders
-28.76
-26.17%
-22.79
-8.96%
-20.92
-14.32%
-18.30
Depreciation Amortization Depletion Income Statement
—
0.30
-2.75%
0.30
+5.18%
0.29
Depreciation And Amortization In Income Statement
—
0.30
-2.75%
0.30
+5.18%
0.29
Depreciation Income Statement
—
0.30
-2.75%
0.30
+5.18%
0.29
Line Item Trend 2023-12-31
Total Assets
29.26
Current Assets
28.78
Cash Cash Equivalents And Short Term Investments
26.32
Cash And Cash Equivalents
26.32
Other Short Term Investments
0.00
Receivables
0.01
Other Receivables
0.01
Prepaid Assets
2.45
Hedging Assets Current
0.00
Total Non Current Assets
0.49
Net PPE
0.49
Gross PPE
1.01
Accumulated Depreciation
-0.52
Properties
0.00
Machinery Furniture Equipment
0.52
Other Properties
0.05
Leases
0.45
Non Current Prepaid Assets
0.00
Total Liabilities Net Minority Interest
8.49
Current Liabilities
3.19
Payables And Accrued Expenses
2.69
Payables
0.82
Accounts Payable
0.82
Current Accrued Expenses
1.88
Current Debt And Capital Lease Obligation
0.10
Current Capital Lease Obligation
0.10
Other Current Liabilities
0.40
Total Non Current Liabilities Net Minority Interest
5.29
Long Term Debt And Capital Lease Obligation
0.22
Long Term Capital Lease Obligation
0.22
Non Current Deferred Liabilities
5.07
Non Current Deferred Revenue
5.07
Stockholders Equity
20.78
Common Stock Equity
20.78
Capital Stock
324.82
Common Stock
324.82
Share Issued
74.42
Ordinary Shares Number
74.42
Treasury Shares Number
0.00
Additional Paid In Capital
31.75
Retained Earnings
-336.20
Gains Losses Not Affecting Retained Earnings
0.41
Other Equity Adjustments
0.41
Total Equity Gross Minority Interest
20.78
Total Capitalization
20.78
Working Capital
25.58
Invested Capital
20.78
Total Debt
0.32
Capital Lease Obligations
0.32
Net Tangible Assets
20.78
Tangible Book Value
20.78
Other Equity Interest
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-20.11
-1.15%
-19.88
+7.28%
-21.44
-24.62%
-17.21
Cash Flow From Continuing Operating Activities
-20.11
-1.15%
-19.88
+7.28%
-21.44
-24.62%
-17.21
Net Income From Continuing Operations
-28.76
-26.17%
-22.79
-8.96%
-20.92
-14.32%
-18.30
Depreciation Amortization Depletion
0.07
-19.54%
0.09
-71.36%
0.30
+5.18%
0.29
Depreciation
0.07
-19.54%
0.09
-71.36%
0.30
+5.18%
0.29
Depreciation And Amortization
0.07
-19.54%
0.09
-71.36%
0.30
+5.18%
0.29
Other Non Cash Items
4.20
+1312.46%
0.30
+454.93%
0.05
+195.58%
-0.06
Stock Based Compensation
3.10
+56.61%
1.98
+27.14%
1.56
-11.03%
1.75
Operating Gains Losses
0.10
+104.95%
-1.98
+47.55%
-3.77
-218.90%
-1.18
Gain Loss On Investment Securities
0.23
+120.10%
-1.17
+70.66%
-3.98
-27134.53%
0.01
Net Foreign Currency Exchange Gain Loss
-0.14
+83.07%
-0.81
-480.57%
0.21
+117.75%
-1.20
Change In Working Capital
1.18
-53.23%
2.52
+89.63%
1.33
+361.82%
0.29
Change In Receivables
2.94
+8485.71%
-0.04
-109.18%
0.38
+50.05%
0.25
Changes In Account Receivables
2.93
+73200.00%
0.00
—
—
Change In Prepaid Assets
0.58
-41.47%
0.99
+69.20%
0.59
+163.75%
-0.92
Change In Payables And Accrued Expense
-0.36
-140.72%
0.88
+1603.48%
-0.06
-104.80%
1.22
Change In Accrued Expense
-0.36
-140.72%
0.88
—
—
Change In Other Working Capital
-1.68
-279.70%
0.94
+444.60%
0.17
+1472.11%
-0.01
Change In Other Current Liabilities
-0.29
-15.81%
-0.25
-201.09%
0.25
+196.49%
-0.26
Investing Cash Flow
-0.01
+96.55%
-0.17
-101.14%
15.24
+201.40%
-15.03
Cash Flow From Continuing Investing Activities
-0.01
+96.55%
-0.17
-101.14%
15.24
+201.40%
-15.03
Net PPE Purchase And Sale
-0.01
+96.55%
-0.17
-2785.35%
-0.01
+85.12%
-0.04
Purchase Of PPE
-0.01
+96.55%
-0.17
-2785.35%
-0.01
+85.12%
-0.04
Capital Expenditure
-0.01
+96.55%
-0.17
-2785.35%
-0.01
+85.12%
-0.04
Net Investment Purchase And Sale
—
0.00
-100.00%
15.25
+201.71%
-14.99
Purchase Of Investment
—
0.00
0.00
+100.00%
-14.99
Sale Of Investment
—
0.00
-100.00%
15.25
0.00
Financing Cash Flow
14.12
+180.83%
5.03
-79.15%
24.12
+168.19%
8.99
Cash Flow From Continuing Financing Activities
14.12
+180.83%
5.03
-79.15%
24.12
+168.19%
8.99
Net Issuance Payments Of Debt
—
-0.24
+20.97%
-0.31
-9.29%
-0.28
Repayment Of Debt
—
-0.24
+20.97%
-0.31
-9.29%
-0.28
Long Term Debt Payments
—
-0.24
+20.97%
-0.31
-9.29%
-0.28
Net Long Term Debt Issuance
—
-0.24
+20.97%
-0.31
-9.29%
-0.28
Net Common Stock Issuance
11.77
+136.24%
4.98
-79.10%
23.84
+157.27%
9.26
Proceeds From Stock Option Exercised
2.38
+4963.83%
0.05
-92.02%
0.59
+6558.46%
0.01
Net Other Financing Charges
-0.03
—
—
—
Changes In Cash
-6.00
+60.09%
-15.03
-183.88%
17.92
+177.06%
-23.25
Effect Of Exchange Rate Changes
0.12
+141.87%
-0.29
+26.55%
-0.39
-127.29%
1.44
Beginning Cash Position
11.08
-58.03%
26.40
+200.17%
8.79
-71.07%
30.40
End Cash Position
5.20
-53.05%
11.08
-57.90%
26.32
+206.17%
8.60
Free Cash Flow
-20.12
-0.30%
-20.06
+6.50%
-21.45
-24.36%
-17.25
Income Tax Paid Supplemental Data
—
0.13
+41.73%
0.09
+166.89%
0.03
Common Stock Issuance
11.77
+136.24%
4.98
-79.10%
23.84
+157.27%
9.26
Issuance Of Capital Stock
11.77
+136.24%
4.98
-79.10%
23.84
+157.27%
9.26
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category